GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen YHLO Biotech Co Ltd (SHSE:688575) » Definitions » Piotroski F-Score

Shenzhen YHLO Biotech Co (SHSE:688575) Piotroski F-Score : 5 (As of Jan. 18, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Shenzhen YHLO Biotech Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shenzhen YHLO Biotech Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shenzhen YHLO Biotech Co's Piotroski F-Score or its related term are showing as below:

SHSE:688575' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 7
Current: 5

During the past 7 years, the highest Piotroski F-Score of Shenzhen YHLO Biotech Co was 7. The lowest was 3. And the median was 4.


Shenzhen YHLO Biotech Co Piotroski F-Score Historical Data

The historical data trend for Shenzhen YHLO Biotech Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen YHLO Biotech Co Piotroski F-Score Chart

Shenzhen YHLO Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 4.00 5.00 3.00

Shenzhen YHLO Biotech Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 6.00 4.00 5.00

Competitive Comparison of Shenzhen YHLO Biotech Co's Piotroski F-Score

For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen YHLO Biotech Co's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shenzhen YHLO Biotech Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 69.999 + 66.035 + 106.994 + 45.609 = ¥289 Mil.
Cash Flow from Operations was 416.673 + 70.007 + 70.625 + 177.284 = ¥735 Mil.
Revenue was 508.164 + 431.323 + 528.707 + 433.826 = ¥1,902 Mil.
Gross Profit was 341.784 + 268.89 + 328.829 + 289.977 = ¥1,229 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(3768.237 + 3806.083 + 3862.262 + 4040.539 + 4087.553) / 5 = ¥3912.9348 Mil.
Total Assets at the begining of this year (Sep23) was ¥3,768 Mil.
Long-Term Debt & Capital Lease Obligation was ¥541 Mil.
Total Current Assets was ¥1,805 Mil.
Total Current Liabilities was ¥888 Mil.
Net Income was 138.902 + 81.238 + 60.295 + 143.483 = ¥424 Mil.

Revenue was 851.765 + 659.996 + 414.971 + 469.97 = ¥2,397 Mil.
Gross Profit was 384.85 + 292.511 + 237.792 + 294.203 = ¥1,209 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(3427.144 + 4213.67 + 3742.871 + 3582.6 + 3768.237) / 5 = ¥3746.9044 Mil.
Total Assets at the begining of last year (Sep22) was ¥3,427 Mil.
Long-Term Debt & Capital Lease Obligation was ¥374 Mil.
Total Current Assets was ¥1,898 Mil.
Total Current Liabilities was ¥879 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shenzhen YHLO Biotech Co's current Net Income (TTM) was 289. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shenzhen YHLO Biotech Co's current Cash Flow from Operations (TTM) was 735. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=288.637/3768.237
=0.07659736

ROA (Last Year)=Net Income/Total Assets (Sep22)
=423.918/3427.144
=0.12369425

Shenzhen YHLO Biotech Co's return on assets of this year was 0.07659736. Shenzhen YHLO Biotech Co's return on assets of last year was 0.12369425. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shenzhen YHLO Biotech Co's current Net Income (TTM) was 289. Shenzhen YHLO Biotech Co's current Cash Flow from Operations (TTM) was 735. ==> 735 > 289 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=540.835/3912.9348
=0.13821723

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=373.54/3746.9044
=0.09969296

Shenzhen YHLO Biotech Co's gearing of this year was 0.13821723. Shenzhen YHLO Biotech Co's gearing of last year was 0.09969296. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=1805.236/887.664
=2.03369293

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=1897.561/878.654
=2.15962256

Shenzhen YHLO Biotech Co's current ratio of this year was 2.03369293. Shenzhen YHLO Biotech Co's current ratio of last year was 2.15962256. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shenzhen YHLO Biotech Co's number of shares in issue this year was 572.561. Shenzhen YHLO Biotech Co's number of shares in issue last year was 577.831. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1229.48/1902.02
=0.6464075

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1209.356/2396.702
=0.50459173

Shenzhen YHLO Biotech Co's gross margin of this year was 0.6464075. Shenzhen YHLO Biotech Co's gross margin of last year was 0.50459173. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=1902.02/3768.237
=0.50475063

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=2396.702/3427.144
=0.69932924

Shenzhen YHLO Biotech Co's asset turnover of this year was 0.50475063. Shenzhen YHLO Biotech Co's asset turnover of last year was 0.69932924. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shenzhen YHLO Biotech Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Shenzhen YHLO Biotech Co  (SHSE:688575) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shenzhen YHLO Biotech Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Shenzhen YHLO Biotech Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen YHLO Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
Baolong 2nd Road, Baolong Street, Building 1, Yahuilong Biological Technology Factory, Longgang District, Guangdong, Shenzhen, CHN, 518116
Shenzhen YHLO Biotech Co Ltd is an innovative enterprise focusing on overall clinical laboratory solutions with leading domestic technology and integrated research, production and marketing. Its main business is research and development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay.
Executives
Xiao Yu Jin senior management
Liao Li Sheng Directors, senior managers
Pang Shi Hong senior management
Song Yong Bo Directors, senior managers
Hu Kun Hui Director
Xia Fu Zhen Core technical personnel

Shenzhen YHLO Biotech Co Headlines

No Headlines